Nano-Liposomal Delivery Systems and their Applications in Bacterial Resistance
DOI:
https://doi.org/10.32947/ajps.v25i4.1255Keywords:
Nanoliposomes, Antibiotic resistance, Drug delivery, Antibacterial agentsAbstract
Nanotechnology has been introduced in several health-related aspects, particularly in therapy. Delivery therapeutic agents using nanoliposomes have approved several improvements in their physiochemical properties, selectivity, potency, and general pharmacokinetics and pharmacodynamics.
Antibiotic resistance is a major threat to the healthcare system in therapeutic and economic aspects. Developing systems of nano-sized antibacterial agents delivered by nano-liposomes shows a promising solution that would increase the effectiveness, decrease the required therapeutic doses, and save the health economy. Various types of nanoliposomes were incorporated including the cationic, anionic, and neutrally charged molecules, this technology targeted G-negative, G-positive, fungal strains, and other pathogens. Nanoliposomes could overcome the dilemma of biofilm formation and enhance selective targeting of the antibiotic agent.
References
1- Ghosh, R., & De, M. (2023). Liposome-based antibacterial delivery: An emergent approach to combat bacterial infections. ACS Omega, 8(39), 35442–35451.
2- Ezzat, H., Rady, M., Hathout, R. M., Abdel-Halim, M., & Mansour, S. (2021). Enhanced anti-bacterial effect of kojic acid using gelatinized core liposomes: A potential approach to combat antibiotic resistance. Journal of Drug Delivery Science and Technology, 64, 102625.
3- Nwabuife, J. C., Pant, A. M., & Govender, T. (2021). Liposomal delivery systems and their applications against Staphylococcus aureus and methicillin-resistant Staphylococcus aureus. Advanced Drug Delivery Reviews, 178, 113861.
4- Arévalo, L. M., Yarce, C. J., Oñate-Garzón, J., & Salamanca, C. H. (2019). Decrease of antimicrobial resistance through polyelectrolyte-coated nanoliposomes loaded with β-lactam drug. Pharmaceuticals, 12(1), 1–11.
5- Grandi, G., Franceschini, R., Valeriani, F., & Tarquini, R. (2022). In vitro antimicrobial activity of ozonated oil in liposome eyedrop against multidrug-resistant bacteria. Open Medicine, 17(1), 1057–1063.
6- Kalhapure, R. S., Suleman, N., Mocktar, C., Seedat, N., & Govender, T. (2015). Nanoengineered drug delivery systems for enhancing antibiotic therapy. Journal of Pharmaceutical Sciences, 104(3), 872–905.
7- Dubald, M., Bourgeois, S., Andrieu, V., & Fessi, H. (2018). Ophthalmic drug delivery systems for antibiotherapy: A review. Pharmaceutics, 10(1).
8- Shchelik, I. S., Sieber, S., & Gademann, K. (2020). Green algae as a drug delivery system for the controlled release of antibiotics. Chemistry - A European Journal, 26(70), 16644–16648.
9- Drulis-Kawa, Z., & Dorotkiewicz-Jach, A. (2010). Liposomes as delivery systems for antibiotics. International Journal of Pharmaceutics, 387(1–2), 187–198.
10- Mahmood, T. H., et al. (2023). Development of PEGylated nano-phytosome formulation with oleuropein and rutin to compare anti-colonic cancer activity with Olea europaea leaves extract. Chemistry & Biodiversity, 20(8), 1–9.
11- Fielding, R. M., & Lasic, D. D. (1999). Liposomes in the treatment of infectious diseases. Ashley Publications.
12- Gonzalez Gomez, A., & Hosseinidoust, Z. (2020). Liposomes for antibiotic encapsulation and delivery. ACS Infectious Diseases, 6(5), 896–908.
13- Nakhaei, P., et al. (2021). Liposomes: Structure, biomedical applications, and stability parameters with emphasis on cholesterol. Frontiers in Bioengineering and Biotechnology, 9, 1–23.
14- Li, M., et al. (2019). Composition design and medical application of liposomes. European Journal of Medicinal Chemistry, 164, 640–653.
15- Nsairat, H., Khater, D., Sayed, U., Odeh, F., Al Bawab, A., & Alshaer, W. (2022). Liposomes: Structure, composition, types, and clinical applications. Heliyon, 8(5), e09394.
16- National Center for Biotechnology Information. (n.d.). Liposome. PubChem Compound Summary. Retrieved January 30, 2025, from https://pubchem.ncbi.nlm.nih.gov/compound/Liposome.
17- Tseu, G. Y. W., & Kamaruzaman, K. A. (2023). A review of different types of liposomes and their advancements as a form of gene therapy treatment for breast cancer. Molecules, 28(3), 31498.
18- Farooque, F., Wasi, M., & Mughees, M. M. (2021). Liposomes as drug delivery system: An updated review. Journal of Drug Delivery and Therapeutics, 11(5-S), 149–158.
19- Tutunji, L. F. (2021). Liposomes as drug delivery systems. EC Pharmacology and Toxicology, 1, 57–68.
20- Olusanya, T. O. B., Ahmad, R. R. H., Ibegbu, D. M., Smith, J. R., & Elkordy, A. A. (2018). Liposomal drug delivery systems and anticancer drugs. Molecules, 23(4), 1–17.
21- Akbarzadeh, A., et al. (2013). Liposome: Classification, preparation, and applications. Nanoscale Research Letters, 8, 1–9.
22- Veloso, D. F., et al. (2018). Intravenous delivery of a liposomal formulation of voriconazole improves drug pharmacokinetics, tissue distribution, and enhances antifungal activity. Drug Delivery, 25(1), 1585–1594.
23- Nicolosi, D., et al. (2010). Encapsulation in fusogenic liposomes broadens the spectrum of action of vancomycin against Gram-negative bacteria. International Journal of Antimicrobial Agents, 35(6), 553–558.
24- Zahra, M. J., et al. (2017). Evaluation and study of antimicrobial activity of nanoliposomal meropenem against Pseudomonas aeruginosa isolates. Artificial Cells, Nanomedicine, and Biotechnology, 45(5), 975–980.
25- Makhlouf, Z., Ali, A. A., & Al-Sayah, M. H. (2023). Liposomes-based drug delivery systems of anti-biofilm agents to combat bacterial biofilm formation. Antibiotics, 12(5), 875.
26- Breijyeh, Z., Jubeh, B., & Karaman, R. (2020). Resistance of Gram-negative bacteria to current antibacterial agents and approaches to resolve it. Molecules, 25(6), 1340.
27- Tula, U. K., et al. (2023). A review on liposomes as a drug delivery system. International Journal of Pharmaceutical and Analytical Research, 12(3), 346–357.
28- Saraf, S., et al. (2020). Advances in liposomal drug delivery to cancer: An overview. Journal of Drug Delivery Science and Technology, 56, 101549.
29- Vyas, H. P., et al. (2015). Enhanced activity of antibiotics by liposomal drug delivery. An International Journal, 1(1), 67–77.
30- Breijyeh, Z., Jubeh, B., & Karaman, R. (2020). Resistance of Gram-Negative Bacteria to Current Antibacterial Agents and Approaches to Resolve It. Molecules (Basel, Switzerland), 25(6), 1340.
31- Zhang, G. E., Meredith, T. C., & Kahne, D. (2013). On the essentiality of lipopolysaccharide to Gram-negative bacteria. Current Opinion in Microbiology, 16(6), 779–785.
32- Bertani, B., & Ruiz, N. (2018). Function and biogenesis of lipopolysaccharides. EcoSal Plus, 8(1), 10–1128.
33- Ibaraki, H., Kanazawa, T., Chien, W. Y., Nakaminami, H., Aoki, M., Ozawa, K., ... & Seta, Y. (2020). The effects of surface properties of liposomes on their activity against Pseudomonas aeruginosa PAO-1 biofilm. Journal of Drug Delivery Science and Technology, 57, 101754.
34- Hou, Y., Wang, Z., Zhang, P., Bai, H., Sun, Y., Duan, J., & Mu, H. (2017). Lysozyme-associated liposomal gentamicin inhibits bacterial biofilm. International Journal of Molecular Sciences, 18(4), 784.
35- Alzahrani, N. M., Booq, R. Y., Aldossary, A. M., Bakr, A. A., Almughem, F. A., Alfahad, A. J., ... & Alshehri, A. A. (2022). Liposome-encapsulated tobramycin and IDR-1018 peptide mediated biofilm disruption and enhanced antimicrobial activity against Pseudomonas aeruginosa. Pharmaceutics, 14(5), 960.
36- Alhariri, M., Majrashi, M. A., Bahkali, A. H., Almajed, F. S., Azghani, A. O., Khiyami, M. A., ... & Halwani, M. A. (2017). Efficacy of neutral and negatively charged liposome-loaded gentamicin on planktonic bacteria and biofilm communities. International Journal of Nanomedicine, 12, 6949–6961.
37- Mai, B., Gao, Y., Li, M., Jia, M., Liu, S., Wang, X., ... & Wang, P. (2021). Tailoring the cationic lipid composition of lipo-DVDMS augments the phototherapy efficiency of burn infection. Biomaterials Science, 9(6), 2053–2066.
38- Zou, L., Hu, D., Wang, F., Jin, Q., & Ji, J. (2022). The relief of hypoxic microenvironment using an O2 self-sufficient fluorinated nanoplatform for enhanced photodynamic eradication of bacterial biofilms. Nano Research, 15(2), 1636–1644.
39- Niaz, T., Shabbir, S., Noor, T., & Imran, M. (2019). Antimicrobial and antibiofilm potential of bacteriocin-loaded nano-vesicles functionalized with rhamnolipids against foodborne pathogens. LWT, 116, 108583.
40- Xu, M., Hu, Y., Xiao, Y., Zhang, Y., Sun, K., Wu, T., ... & Li, J. (2020). Near-infrared-controlled nanoplatform exploiting photothermal promotion of peroxidase-like and OXD-like activities for potent antibacterial and anti-biofilm therapies. ACS Applied Materials & Interfaces, 12(45), 50260–50274.
41- Boccalini, G., Conti, L., Montis, C., Bani, D., Bencini, A., Berti, D., ... & Valtancoli, B. (2017). Methylene blue-containing liposomes as new photodynamic antibacterial agents. Journal of Materials Chemistry B, 5(15), 2788–2797.
42- Aljihani, S. A., Alehaideb, Z., Alarfaj, R. E., Alghoribi, M. F., Akiel, M. A., Alenazi, T. H., ... & Halwani, M. A. (2020). Enhancing azithromycin antibacterial activity by encapsulation in liposomes/liposomal-N-acetylcysteine formulations against resistant clinical strains of Escherichia coli. Saudi Journal of Biological Sciences, 27(11), 3065–3071.
43- Vanić, Ž., Rukavina, Z., Manner, S., Fallarero, A., Uzelac, L., Kralj, M., ... & Škalko-Basnet, N. (2019). Azithromycin-liposomes as a novel approach for localized therapy of cervicovaginal bacterial infections. International Journal of Nanomedicine, 5957–5976.
44- Cui, H., Zhang, C., Li, C., & Lin, L. (2020). Inhibition of Escherichia coli O157
biofilm on vegetable surface by solid liposomes of clove oil. LWT, 117, 108656.
45- Fu, Y. Y., Zhang, L., Yang, Y., Liu, C. W., He, Y. N., Li, P., & Yu, X. (2019). Synergistic antibacterial effect of ultrasound microbubbles combined with chitosan-modified polymyxin B-loaded liposomes on biofilm-producing Acinetobacter baumannii. International Journal of Nanomedicine, 14, 1805–1815.
46- Pourhajibagher, M., Partoazar, A., Alaeddini, M., Etemad-Moghadam, S., & Bahador, A. (2020). Photodisinfection effects of silver sulfadiazine nanoliposomes doped-curcumin on Acinetobacter baumannii: A mouse model. Nanomedicine, 15(5), 437–452.
47- Allemailem, K. S., Almatroudi, A., Alrumaihi, F., Aljaghwani, A., Alnuqaydan, A. M., Khalilullah, H., ... & Khan, M. A. (2021). Antimicrobial, immunomodulatory, and anti-inflammatory potential of liposomal thymoquinone: Implications in the treatment of bacterial pneumonia in immunocompromised mice. Biomedicines, 9(11), 1673.
48- Ekonomou, S. I., Thanekar, P. A., Lamprou, D. A., Weaver, E., Doran, O., & Stratakos, A. C. (2022). Development of geraniol-loaded liposomal nanoformulations against Salmonella colonization in the pig gut. Journal of Agricultural and Food Chemistry, 70(23), 7004–7014.
49- Jubeh, B., Breijyeh, Z., & Karaman, R. (2020). Resistance of gram-positive bacteria to current antibacterial agents and overcoming approaches. Molecules, 25(12), 2888.
50- Oliva, A., Stefani, S., Venditti, M., & Di Domenico, E. G. (2021). Biofilm-related infections in gram-positive bacteria and the potential role of the long-acting agent dalbavancin. Frontiers in Microbiology, 12, 749685.
51- Aiello, S., Pagano, L., Ceccacci, F., Simonis, B., Sennato, S., Bugli, F., ... & Mancini, G. (2021). Mannosyl, glucosyl, or galactosyl liposomes to improve resveratrol efficacy against methicillin-resistant Staphylococcus aureus biofilm. Colloids and Surfaces A: Physicochemical and Engineering Aspects, 617, 126321.
52- Wang, Z., Liu, X., Peng, Y., Su, M., Zhu, S., Pan, J., ... & Huang, Y. (2020). Platensimycin-encapsulated liposomes or micelles as biosafe nanoantibiotics exhibited strong antibacterial activities against methicillin-resistant Staphylococcus aureus infection in mice. Molecular Pharmaceutics, 17(7), 2451–2462.
53- Rukavina, Z., Klarić, M. Š., Filipović-Grčić, J., Lovrić, J., & Vanić, Ž. (2018). Azithromycin-loaded liposomes for enhanced topical treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections. International Journal of Pharmaceutics, 553(1–2), 109–119.
54- Alavi, S. E., Esfahani, M. K. M., Raza, A., Adelnia, H., & Shahmabadi, H. E. (2022). PEG-grafted liposomes for enhanced antibacterial and antibiotic activities: An in vivo study. NanoImpact, 25, 100384.
55- Altube, M. J., Martínez, M. M., Malheiros, B., Maffía, P. C., Barbosa, L. R., Morilla, M. J., & Romero, E. L. (2019). Fast biofilm penetration and anti-PAO1 activity of nebulized azithromycin in nanoarchaeosomes. Molecular Pharmaceutics, 17(1), 70–83.
56- Silva, M. D., Paris, J. L., Gama, F. M., Silva, B. F., & Sillankorva, S. (2021). Sustained release of a Streptococcus pneumoniae endolysin from liposomes for potential otitis media treatment. ACS Infectious Diseases, 7(8), 2127–2137.
57- Qiu, Y., Xu, D., Sui, G., Wang, D., Wu, M., Han, L., ... & Duan, J. (2020). Gentamicin-decorated phosphatidylcholine-chitosan nanoparticles against biofilms and intracellular bacteria. International Journal of Biological Macromolecules, 156, 640–647.
58- Zhao, Y., Dai, X., Wei, X., Yu, Y., Chen, X., Zhang, X., & Li, C. (2018). Near-infrared light-activated thermosensitive liposomes as efficient agents for photothermal and antibiotic synergistic therapy of bacterial biofilm. ACS Applied Materials & Interfaces, 10(17), 14426–14437.
59- Samaranayake, L. (2018). Essential Microbiology for Dentistry-E-Book. Elsevier Health Sciences.
60- Tolker-Nielsen, T. (2015). Biofilm development. Microbial Biofilms, 51–66.
61- Wang, Y., Lee, S. M., & Dykes, G. (2015). The physicochemical process of bacterial attachment to abiotic surfaces: Challenges for mechanistic studies, predictability, and the development of control strategies. Critical Reviews in Microbiology, 41(4), 452–464.
62- Lebeaux, D., Ghigo, J. M., & Beloin, C. (2014). Biofilm-related infections: Bridging the gap between clinical management and fundamental aspects of recalcitrance toward antibiotics. Clinical Microbiology Reviews, 27(4), 649–691.
63- Wang, Y. (2021). Liposome as a delivery system for the treatment of biofilm-mediated infections. Journal of Applied Microbiology, 131(6), 2626–2639.
64- Riaz, M. K., Riaz, M. A., Zhang, X., Lin, C., Wong, K. H., Chen, X., ... & Yang, Z. (2018). Surface functionalization and targeting strategies of liposomes in solid tumor therapy: A review. International Journal of Molecular Sciences, 19(1), 195.
65- [65] Xue, H., Guo, P., Wen, W. C., & Lun Wong, H. (2015). Lipid-based nanocarriers for RNA delivery. Current Pharmaceutical Design, 21(22), 3140–3147.
66- [66] Liu, Y., Busscher, H. J., Zhao, B., Li, Y., Zhang, Z., van der Mei, H. C., ... & Shi, L. (2016). Surface-adaptive, antimicrobially loaded, micellar nanocarriers with enhanced penetration and killing efficiency in staphylococcal biofilms. ACS Nano, 10(4), 4779–4789.
67- Peeridogaheh, H., Pourhajibagher, M., Barikani, H. R., & Bahador, A. (2019). The impact of Aggregatibacter actinomycetemcomitans biofilm-derived effectors following antimicrobial photodynamic therapy on cytokine production in human gingival fibroblasts. Photodiagnosis and Photodynamic Therapy, 27, 1–6.
68- Ash, A., Mulholland, F., Burnett, G. R., & Wilde, P. J. (2014). Structural and compositional changes in the salivary pellicle induced upon exposure to SDS and STP. Biofouling, 30(10), 1183–1197.
69- Fernandes, T., Bhavsar, C., Sawarkar, S., & D’Souza, A. (2018). Current and novel approaches for control of dental biofilm. International Journal of Pharmaceutics, 536(1), 199–210.
70- Pistone, S., Rykke, M., Smistad, G., & Hiorth, M. (2017). Polysaccharide-coated liposomal formulations for dental targeting. International Journal of Pharmaceutics, 516(1–2), 106–115.
71- Robinson, A. M., Bannister, M., Creeth, J. E., & Jones, M. N. (2001). The interaction of phospholipid liposomes with mixed bacterial biofilms and their use in the delivery of bactericide. Colloids and Surfaces A: Physicochemical and Engineering Aspects, 186(1–2), 43–53.
72- Catuogno, C., & Jones, M. N. (2003). The antibacterial properties of solid-supported liposomes on Streptococcus oralis biofilms. International Journal of Pharmaceutics, 257(1–2), 125–140.
73- Jones, M. N., Song, Y. H., Kaszuba, M., & Reboiras, M. D. (1997). The interaction of phospholipid liposomes with bacteria and their use in the delivery of bactericides. Journal of Drug Targeting, 5(1), 25–34.
74- He, Y., Vasilev, K., & Zilm, P. (2023). pH-responsive biomaterials for the treatment of dental caries—A focused and critical review. Pharmaceutics, 15(7), 1837.
75- Bassetti, M., Vena, A., Croxatto, A., Righi, E., & Guery, B. (2018). How to manage Pseudomonas aeruginosa infections. Drugs in Context, 7, 1–19.
76- Hirsch, E. B., & Tam, V. H. (2010). Impact of multidrug-resistant Pseudomonas aeruginosa infection on patient outcomes. Expert Review of Pharmacoeconomics & Outcomes Research, 10(4), 441–451.
77- Yang, L., Hu, Y., Liu, Y., Zhang, J., Ulstrup, J., & Molin, S. (2011). Distinct roles of extracellular polymeric substances in Pseudomonas aeruginosa biofilm development. Environmental Microbiology, 13(7), 1705–1717.
78- Martin, C., LiLow, W., Gupta, A., Cairul Iqbal Mohd Amin, M., Radecka, I., Britland, T., & Raj, P. (2015). Strategies for antimicrobial drug delivery to biofilm. Current Pharmaceutical Design, 21(1), 43–66.
79- Beaulac, C., Clement-Major, S., Hawari, J., & Lagace, J. (1996). Eradication of mucoid Pseudomonas aeruginosa with fluid liposome-encapsulated tobramycin in an animal model of chronic pulmonary infection. Antimicrobial Agents and Chemotherapy, 40(3), 665–669.
80- Alipour, M., Dorval, C., Suntres, Z. E., & Omri, A. (2011). Bismuth-ethanedithiol incorporated in a liposome-loaded tobramycin formulation modulates the alginate levels in mucoid Pseudomonas aeruginosa. Journal of Pharmacy and Pharmacology, 63(8), 999–1007.
81- Alhariri, M., & Omri, A. (2013). Efficacy of liposomal bismuth-ethanedithiol-loaded tobramycin after intratracheal administration in rats with pulmonary Pseudomonas aeruginosa infection. Antimicrobial Agents and Chemotherapy, 57(1), 569–578.
82- Omri, A., Suntres, Z. E., & Shek, P. N. (2002). Enhanced activity of liposomal polymyxin B against Pseudomonas aeruginosa in a rat model of lung infection. Biochemical Pharmacology, 64(9), 1407–1413.
83- Alipour, M., Halwani, M., Omri, A., & Suntres, Z. E. (2008). Antimicrobial effectiveness of liposomal polymyxin B against resistant Gram-negative bacterial strains. International Journal of Pharmaceutics, 355(1–2), 293–298.
84- Khatib, I., Khanal, D., Ruan, J., Cipolla, D., Dayton, F., Blanchard, J. D., & Chan, H. K. (2019). Ciprofloxacin nanocrystals liposomal powders for controlled drug release via inhalation. International Journal of Pharmaceutics, 566, 641–651.
85- Torchilin, V. P. (2014). Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery. Nature Reviews Drug Discovery, 13(11), 813–827.
86- [86] Storm, G., & Crommelin, D. J. (1998). Liposomes: Quo vadis? Pharmaceutical Science & Technology Today, 1(1), 19–31.
87- U.S. Food and Drug Administration. (2022). Draft guidance on doxorubicin hydrochloride. FDA Guidance for Industry. Retrieved from https://www.accessdata.fda.gov
88- U.S. Food and Drug Administration. (2018). Liposome drug products: Chemistry, manufacturing, and controls; human pharmacokinetics and bioavailability; and labeling documentation. FDA Guidance for Industry. Retrieved from https://www.accessdata.fda.gov
89- Ministry of Health, Labour and Welfare, Japan. (2016). Guideline for the development of liposome drug products. Retrieved from https://www.mhlw.go.jp
90- ICH Expert Working Group. (2019). ICH guideline Q3C (R6) on impurities: Guideline for residual solvents. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), 1–32.
91- Anderson, M., & Omri, A. (2004). The effect of different lipid components on the in vitro stability and release kinetics of liposome formulations. Drug Delivery, 11(1), 33–39.
92- Shah, S., Dhawan, V., Holm, R., Nagarsenker, M. S., & Perrie, Y. (2020). Liposomes: Advancements and innovation in the manufacturing process. Advanced Drug Delivery Reviews, 154, 102–122.
93- Abraham, S. A., Waterhouse, D. N., Mayer, L. D., Cullis, P. R., Madden, T. D., & Bally, M. B. (2005). The liposomal formulation of doxorubicin. In D. L. Wheeler (Ed.), Methods in enzymology (Vol. 391, pp. 71–97). Academic Press.
94- Rivnay, B., Wakim, J., Avery, K., Petrochenko, P., Myung, J. H., Kozak, D., ... & Nivorozhkin, A. (2019). Critical process parameters in manufacturing of liposomal formulations of amphotericin B. International Journal of Pharmaceutics, 565, 447–457.
95- Laouini, A., Jaafar-Maalej, C., Limayem-Blouza, I., Sfar, S., Charcosset, C., & Fessi, H. (2012). Preparation, characterization and applications of liposomes: State of the art. Journal of Colloid Science and Biotechnology, 1(2), 147–168.
96- Nsairat, H., Khater, D., Sayed, U., Odeh, F., Al Bawab, A., & Alshaer, W. (2022). Liposomes: structure, composition, types, and clinical applications. Heliyon, 8(5), e09394.
97- Mouritsen, O. G., & Jorgensen, K. (1998). A new look at lipid-membrane structure in relation to drug research. Pharmaceutical Research, 15(10), 1507–1519.
98- Gregoriadis, G. (1995). Engineering liposomes for drug delivery: Progress and problems. Trends in Biotechnology, 13(12), 527–537.
99- Ulrich, A. S. (2002). Biophysical aspects of using liposomes as delivery vehicles. Bioscience Reports, 22(2), 129–150.
100- Drulis-Kawa, Z., Gubernator, J., Dorotkiewicz-Jach, A., Doroszkiewicz, W., & Kozubek, A. (2006). In vitro antimicrobial activity of liposomal meropenem against Pseudomonas aeruginosa strains. International Journal of Pharmaceutics, 315(1–2), 59–66.
101- Gubernator, J., Drulis-Kawa, Z., Dorotkiewicz-Jach, A., Doroszkiewicz, W., & Kozubek, A. (2007). In vitro antimicrobial activity of liposomes containing ciprofloxacin, meropenem, and gentamicin against Gram-negative clinical bacterial strains. Letters in Drug Design & Discovery, 4(4), 297–304.
102- Briones, E., Colino, C. I., & Lanao, J. M. (2008). Delivery systems to increase the selectivity of antibiotics in phagocytic cells. Journal of Controlled Release, 125(3), 210–227.
103- Yokouchi, Y., Tsunoda, T., Imura, T., Yamauchi, H., Yokoyama, S., Sakai, H., & Abe, M. (2001). Effect of adsorption of bovine serum albumin on liposomal membrane characteristics. Colloids and Surfaces B: Biointerfaces, 20(2), 95–103.
104- Sharma, A., & Sharma, U. S. (1997). Liposomes in drug delivery: Progress and limitations. International Journal of Pharmaceutics, 154(2), 123–140.
105- Doi, Y., Shimizu, T., Ishima, Y., & Ishida, T. (2019). Long-term storage of PEGylated liposomal oxaliplatin with improved stability and long circulation times in vivo. International Journal of Pharmaceutics, 564, 237–243.
106- Rukavina, Z., & Vanić, Ž. (2016). Current trends in development of liposomes for targeting bacterial biofilms. Pharmaceutics, 8(2), 18.
107- Wagner, A., & Vorauer-Uhl, K. (2011). Liposome technology for industrial purposes. Journal of Drug Delivery, 2011(1), 591325.
108- Stark, B., Pabst, G., & Prassl, R. (2010). Long-term stability of sterically stabilized liposomes by freezing and freeze-drying: Effects of cryoprotectants on structure. European Journal of Pharmaceutical Sciences, 41(3–4), 546–555.
109- Abed, N., & Couvreur, P. (2014). Nanocarriers for antibiotics: A promising solution to treat intracellular bacterial infections. International Journal of Antimicrobial Agents, 43(6), 485–496.
110- Tereshkina, Y. A., Torkhovskaya, T. I., Tikhonova, E. G., Kostryukova, L. V., Sanzhakov, M. A., Korotkevich, E. I., ... & Kolesanova, E. F. (2022). Nanoliposomes as drug delivery systems: Safety concerns. Journal of Drug Targeting, 30(3), 313–325.
111- Mishra, G. P., Bagui, M., Tamboli, V., & Mitra, A. K. (2011). Recent applications of liposomes in ophthalmic drug delivery. Journal of Drug Delivery, 2011(1), 863734.
112- Wu, J., Liu, Q., & Lee, R. J. (2006). A folate receptor-targeted liposomal formulation for paclitaxel. International Journal of Pharmaceutics, 316(1–2), 148–153.
113- Lammers, T., Kiessling, F., Hennink, W. E., & Storm, G. (2012). Drug targeting to tumors: Principles, pitfalls, and (pre-) clinical progress. Journal of Controlled Release, 161(2), 175–187.
114- Gonzalez Gomez, A., Xu, C., & Hosseinidoust, Z. (2019). Preserving the efficacy of glycopeptide antibiotics during nanoencapsulation in liposomes. ACS Infectious Diseases, 5(10), 1794–1801.
115- Kalepu, S., Sunilkumar, K. T., Betha, S., & Mohanvarma, M. (2013). Liposomal drug delivery system—A comprehensive review. International Journal of Drug Development and Research, 5(4), 62–75.
116- Ruiz, A., Herráez, M., Costa-Gutierrez, S. B., Molina-Henares, M. A., Martínez, M. J., Espinosa-Urgel, M., & Barriuso, J. (2021). The architecture of a mixed fungal–bacterial biofilm is modulated by quorum-sensing signals. Environmental Microbiology, 23(5), 2433–2447.
117- Allkja, J., & Azevedo, A. S. (2021). Characterization of social interactions and spatial arrangement of individual bacteria in multistrain or multispecies biofilm systems using nucleic acid mimics-fluorescence in situ hybridization. In Fluorescence In-Situ Hybridization (FISH) for Microbial Cells: Methods and Concepts (pp. 97–109).
118- Chitlapilly Dass, S., Bosilevac, J. M., Weinroth, M., Elowsky, C. G., Zhou, Y., Anandappa, A., & Wang, R. (2020). Impact of mixed biofilm formation with environmental microorganisms on E. coli O157
survival against sanitization. NPJ Science of Food, 4(1), 16.
119- Drulis-Kawa, Z., Dorotkiewicz-Jach, A., Gubernator, J., Gula, G., Bocer, T., & Doroszkiewicz, W. (2010). The interaction between Pseudomonas aeruginosa cells and cationic PC: Chol: DOTAP liposomal vesicles versus outer-membrane structure and envelope properties of bacterial cell. International Journal of Pharmaceutics, 367(1–2), 211–219.
120- Fresta, M., Spadaro, A., Cerniglia, G., Ropero, I. M., Puglisi, G., & Furneri, P. M. (1995). Intracellular accumulation of ofloxacin-loaded liposomes in human synovial fibroblasts. Antimicrobial Agents and Chemotherapy, 39(6), 1372–1375.
121- Sachetelli, S., Khalil, H., Chen, T., Beaulac, C., Sénéchal, S., & Lagacé, J. (2000). Demonstration of a fusion mechanism between a fluid bactericidal liposomal formulation and bacterial cells. Biochimica et Biophysica Acta (BBA)-Biomembranes, 1463(2), 254–266.
122- Mugabe, C., Halwani, M., Azghani, A. O., Lafrenie, R. M., & Omri, A. (2006). Mechanism of enhanced activity of liposome-entrapped aminoglycosides against resistant strains of Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 50(6), 2016–2022.
123- Halwani, M., Mugabe, C., Azghani, A. O., Lafrenie, R. M., Kumar, A., & Omri, A. (2008). Bactericidal efficacy of liposomal aminoglycosides against Burkholderia cenocepacia. Journal of Antimicrobial Chemotherapy, 60(4), 760–769.
124- Hallaj-Nezhadi, S., & Hassan, M. (2015). Nanoliposome-based antibacterial drug delivery. Drug Delivery, 22(5), 581–589.
125- Immordino, M., Dosio, F., & Cattel, L. (2006). Stealth liposomes: Review of the basic science, rationale, and clinical applications, existing and potential. International Journal of Nanomedicine, 1(3), 297–315.
126- Vasir, J. K., Reddy, M. K., & Labhasetwar, V. D. (2005). Nanosystems in drug targeting: Opportunities and challenges. Current Nanoscience, 1(1), 47–64.
127- Toh, M. R., & Chiu, G. N. (2013). Liposomes as sterile preparations and limitations of sterilisation techniques in liposomal manufacturing. Asian Journal of Pharmaceutical Sciences, 8(2), 88–95.
128- Pinheiro, M., Lucio, M., Lima, J. L., & Reis, S. (2011). Liposomes as drug delivery systems for the treatment of TB. Nanomedicine, 6(8), 1413–1428.
129- Liu, Y., Bravo, K. M. C., & Liu, J. (2021). Targeted liposomal drug delivery: A nanoscience and biophysical perspective. Nanoscale Horizons, 6(2), 78–94.
130- Min, Y., Caster, J. M., Eblan, M. J., & Wang, A. Z. (2015). Clinical translation of nanomedicine. Chemical Reviews, 115(19), 11147–11190.
131- Barenholz, Y. C. (2012). Doxil®—The first FDA-approved nano-drug: Lessons learned. Journal of Controlled Release, 160(2), 117–134.
132- Ishida, O., Maruyama, K., Tanahashi, H., Iwatsuru, M., Sasaki, K., Eriguchi, M., & Yanagie, H. (2001). Liposomes bearing polyethyleneglycol-coupled transferrin with intracellular targeting property to the solid tumors in vivo. Pharmaceutical Research, 18, 1042–1048.
133- Li, X., Ding, L., Xu, Y., Wang, Y., & Ping, Q. (2009). Targeted delivery of doxorubicin using stealth liposomes modified with transferrin. International Journal of Pharmaceutics, 373(1–2), 116–123.
134- Torchilin, V. (2008). Antibody-modified liposomes for cancer chemotherapy. Expert Opinion on Drug Delivery, 5(9), 1003–1025.
135- Kirpotin, D. B., Drummond, D. C., Shao, Y., Shalaby, M. R., Hong, K., Nielsen, U. B., ... & Park, J. W. (2006). Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Research, 66(13), 6732–6740.
136- Yamada, A., Taniguchi, Y., Kawano, K., Honda, T., Hattori, Y., & Maitani, Y. (2008). Design of folate-linked liposomal doxorubicin to its antitumor effect in mice. Clinical Cancer Research, 14(24), 8161–8168.
137- Mamot, C., Drummond, D. C., Noble, C. O., Kallab, V., Guo, Z., Hong, K., ... & Park, J. W. (2005). Epidermal growth factor receptor–targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. Cancer Research, 65(24), 11631–11638.
138- Yang, T., Choi, M. K., Cui, F. D., Lee, S. J., Chung, S. J., Shim, C. K., & Kim, D. D. (2007). Antitumor effect of paclitaxel-loaded PEGylated immunoliposomes against human breast cancer cells. Pharmaceutical Research, 24, 2402–2411.
139- Hatakeyama, H., Akita, H., Ishida, E., Hashimoto, K., Kobayashi, H., Aoki, T., ... & Harashima, H. (2007). Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modified PEG liposomes. International Journal of Pharmaceutics, 342(1–2), 194–200.
140- Nagy, N. A., De Haas, A. M., Geijtenbeek, T. B., Van Ree, R., Tas, S. W., Van Kooyk, Y., & De Jong, E. C. (2021). Therapeutic liposomal vaccines for dendritic cell activation or tolerance. Frontiers in Immunology, 12, 674048.
141- Schwendener, R. A. (2014). Liposomes as vaccine delivery systems: A review of the recent advances. Therapeutic Advances in Vaccines, 2(6), 159–182.
142- Kozako, T., Arima, N., Yoshimitsu, M., Honda, S. I., & Soeda, S. (2012). Liposomes and nanotechnology in drug development: Focus on oncotargets. International Journal of Nanomedicine, 7, 4943–4951.
143- Yu, B., Mao, Y., Bai, L. Y., Herman, S. E., Wang, X., Ramanunni, A., ... & Muthusamy, N. (2013). Targeted nanoparticle delivery overcomes off-target immunostimulatory effects of oligonucleotides and improves therapeutic efficacy in chronic lymphocytic leukemia. Blood, 121(1), 136–147.
144- Nakamura, T., Yamazaki, D., Yamauchi, J., & Harashima, H. (2013). The nanoparticulation by octaarginine-modified liposome improves α-galactosylceramide-mediated antitumor therapy via systemic administration. Journal of Controlled Release, 171(2), 216–224.
145- Cruz, L. J., Rueda, F., Simon, L., Cordobilla, B., Albericio, F., & Domingo, J. C. (2014). Liposomes containing NY-ESO-1/tetanus toxoid and adjuvant peptides targeted to human dendritic cells via the Fc receptor for cancer vaccines. Nanomedicine, 9(4), 435–449.
146- Wang, C., Zhuang, Y., Zhang, Y., Luo, Z., Gao, N., Li, P., ... & Ma, Y. (2012). Toll-like receptor 3 agonist complexed with cationic liposome augments vaccine-elicited antitumor immunity by enhancing TLR3–IRF3 signaling and type I interferons in dendritic cells. Vaccine, 30(32), 4790–4799.
147- Tan, C., Wang, J., & Sun, B. (2021). Biopolymer-liposome hybrid systems for controlled delivery of bioactive compounds: Recent advances. Biotechnology Advances, 48, 107727.
148- Tahara, K., Nishio, M., & Takeuchi, H. (2018). Evaluation of liposomal behavior in the gastrointestinal tract after oral administration using real-time in vivo imaging. Drug Development and Industrial Pharmacy, 44(4), 608–614.
149- Nguyen, T. X., Huang, L., Gauthier, M., Yang, G., & Wang, Q. (2016). Recent advances in liposome surface modification for oral drug delivery. Nanomedicine, 11(9), 1169–1185.
150- Peng, S., Zou, L., Liu, W., Li, Z., Liu, W., Hu, X., ... & Liu, C. (2017). Hybrid liposomes composed of amphiphilic chitosan and phospholipid: Preparation, stability, and bioavailability as a carrier for curcumin. Carbohydrate Polymers, 156, 322–332.
151- Gharib, R., Greige-Gerges, H., Fourmentin, S., Charcosset, C., & Auezova, L. (2015). Liposomes incorporating cyclodextrin–drug inclusion complexes: Current state of knowledge. Carbohydrate Polymers, 129, 175–186.
152- Hammoud, Z., Khreich, N., Auezova, L., Fourmentin, S., Elaissari, A., & Greige-Gerges, H. (2019). Cyclodextrin-membrane interaction in drug delivery and membrane structure maintenance. International Journal of Pharmaceutics, 564, 59–76.
153- Palazzo, C., Laloy, J., Delvigne, A. S., Nys, G., Fillet, M., Dogne, J. M., ... & Piel, G. (2019). Development of injectable liposomes and drug-in-cyclodextrin-in-liposome formulations encapsulating estetrol to prevent cerebral ischemia of premature babies. European Journal of Pharmaceutical Sciences, 127, 52–59.
154- [154] Ternullo, S., Schulte Werning, L. V., Holsæter, A. M., & Škalko-Basnet, N. (2019). Curcumin-in-deformable liposomes-in-chitosan-hydrogel as a novel wound dressing. Pharmaceutics, 12(1), 8.
155- [155] Liu, L., Xiang, Y., Wang, Z., Yang, X., Yu, X., Lu, Y., ... & Cui, W. (2019). Adhesive liposomes loaded onto an injectable, self-healing, and antibacterial hydrogel for promoting bone reconstruction. NPG Asia Materials, 11(1), 81.
156- [156] Mohammadi, M., Alibolandi, M., Abnous, K., Salmasi, Z., Jaafari, M. R., & Ramezani, M. (2018). Fabrication of hybrid scaffold based on hydroxyapatite-biodegradable nanofibers incorporated with liposomal formulation of BMP-2 peptide for bone tissue engineering. Nanomedicine: Nanotechnology, Biology and Medicine, 14(7), 1987–1997.
157- [157] Jindal, S., Awasthi, R., Singhare, D., & Kulkarni, G. T. (2020). Topical delivery of tacrolimus using liposome-containing gel: An emerging and synergistic approach in management of psoriasis. Medical Hypotheses, 142, 109838.
158- [158] Andrade, J., González-Martínez, C., & Chiralt, A. (2020). The incorporation of carvacrol into poly (vinyl alcohol) films encapsulated in lecithin liposomes. Polymers, 12(2), 497.
159- [159] Panja, S., Khatua, D. K., & Halder, M. (2019). Effect of casein on pure lecithin liposome: Mixed biomacromolecular system for providing superior stabilization to hydrophobic molecules. Colloids and Surfaces B: Biointerfaces, 180, 298–305.
160- [160] Odeh, F., Nsairat, H., Alshaer, W., Alsotari, S., Buqaien, R., Ismail, S., ... & Al Bawab, A. (2019). Remote loading of curcumin-in-modified β-cyclodextrins into liposomes using a transmembrane pH gradient. RSC Advances, 9(64), 37148–37161.
161- [161] Jhan, S., & Pethe, A. M. (2020). Double-loaded liposomes encapsulating lycopene β-cyclodextrin complexes: Preparation, optimization, and evaluation. Journal of Liposome Research, 30(1), 80–92.
162- [162] Soo, E., Thakur, S., Qu, Z., Jambhrunkar, S., Parekh, H. S., & Popat, A. (2016). Enhancing delivery and cytotoxicity of resveratrol through a dual nanoencapsulation approach. Journal of Colloid and Interface Science, 462, 368–374.
163- [163] Fernández-Romero, A. M., Maestrelli, F., Mura, P. A., Rabasco, A. M., & González-Rodríguez, M. L. (2018). Novel findings about double-loaded curcumin-in-HPβ-cyclodextrin-in-liposomes: Effects on the lipid bilayer and drug release. Pharmaceutics, 10(4), 256.
164- [164] Peyman, G. A., Charles, H. C., Liu, K. R., Khoobehi, B., & Niesman, M. (1988). Intravitreal liposome-encapsulated drugs: A preliminary human report. International Ophthalmology, 12, 175–182.
165- [165] Nightingale, S. D., Saletan, S. L., Swenson, C. E., Lawrence, A. J., Watson, D. A., Pilkiewicz, F. G., ... & Cal, S. X. (1993). Liposome-encapsulated gentamicin treatment of Mycobacterium avium-Mycobacterium intracellulare complex bacteremia in AIDS patients. Antimicrobial Agents and Chemotherapy, 37(9), 1869–1872.
166- [167] Wiley, E. L., Perry, A., Nightingale, S. D., & Lawrence, J. (1994). Detection of Mycobacterium avium-intracellulare complex in bone marrow specimens of patients with acquired immunodeficiency syndrome. American Journal of Clinical Pathology, 101(4), 446–451.
167- [168] Brandissou, S., Hamel, B., Veillet, B., Kinowski, J. M., Yagoubi, N., & Bressolle, F. (1997). Mycobacterium avium complex infections: The point on the treatments. Therapie, 52(1), 65–71.
168- [169] Sesin, G. P., Manzi, S. F., & Pacheco, R. (1996). New trends in the drug therapy of localized and disseminated Mycobacterium avium complex infection. American Journal of Health-System Pharmacy, 53(21), 2585–2590.
169- [170] Donald, P. R., Sirgel, F. A., Venter, A., Smit, E., Parkin, D. P., Van de Wal, B. W., & Mitchison, D. A. (2001). The early bactericidal activity of a low-clearance liposomal amikacin in pulmonary tuberculosis. Journal of Antimicrobial Chemotherapy, 48(6), 877–880.
170- [171] Krieger, J., Childs, S., & Klimberg, I. (1999, March). Urinary tract infection treatment using liposomal amikacin (MiKasome). In Proceedings of the Ninth European Congress of Clinical Microbiology and Infectious Diseases, Berlin, Germany (pp. 21–24).
171- [172] Li, Z., Zhang, Y., Wurtz, W., Lee, J. K., Malinin, V. S., Durwas-Krishnan, S., ... & Perkins, W. R. (2008). Characterization of nebulized liposomal amikacin (Arikace™) as a function of droplet size. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 21(3), 245–254.
172- [173] Dupont, L., Minic, P., Fustic, S., Mazurek, H., Solyom, E., Feketova, A., ... & Gupta, R. (2008). A randomized placebo-controlled study of nebulized liposomal amikacin (Arikace™) in the treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. Journal of Cystic Fibrosis, 7(Suppl.), S26.
173- [174] Okusanya, O. O., Bhavnani, S. M., Hammel, J., Minic, P., Dupont, L. J., Forrest, A., ... & Gupta, R. (2009). Pharmacokinetic and pharmacodynamic evaluation of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infection. Antimicrobial Agents and Chemotherapy, 53(9), 3847–3854.
174- [175] Bruinenberg, P., Otulana, B., Blanchard, J., Morishige, R., Cipolla, D., Wilson, J., & Serisier, D. (2008). The effect of once-a-day, inhaled liposomal ciprofloxacin hydrochloride for inhalation on bacterial density in cystic fibrosis patients with P. aeruginosa infection. Pediatric Pulmonology, 43, 401.
175- [176] Buzia, O. D., Bezman, V., Palivan, C. C. M., Topor, G., Tatu, A. L., Kamel, E., & Ionuta, G. (2020). Antibacterial action of certain tretinoin and benzoyl peroxide liposomes: A case study. Romanian Journal of Oral Rehabilitation, 12(4), 22–28.
176- [177] Perrie, Y., Kastner, E., Kaur, R., Wilkinson, A., & Ingham, A. J. (2013). A case-study investigating the physicochemical characteristics that dictate the function of a liposomal adjuvant. Human Vaccines & Immunotherapeutics, 9(6), 1374–1381.
177- [178] Rukholm, G., Mugabe, C., Azghani, A. O., & Omri, A. (2006). Antibacterial activity of liposomal gentamicin against Pseudomonas aeruginosa: A time–kill study. International Journal of Antimicrobial Agents, 27(3), 247–252.
178- [179] Obonyo, M., Zhang, L., Thamphiwatana, S., Pornpattananangkul, D., Fu, V., & Zhang, L. (2012). Antibacterial activities of liposomal linolenic acids against antibiotic-resistant Helicobacter pylori. Molecular Pharmaceutics, 9(9), 2677–2685.
179- [180] Schiffelers, R. M., Storm, G., Bakker-Woudenberg, I. A., & Crommelin, D. J. (2002). Liposome-enabled synergistic interaction of antimicrobial agents. Journal of Liposome Research, 12(1–2), 121–127.
180- [181] Rukavina, Z., & Vanić, Ž. (2016). Current trends in development of liposomes for targeting bacterial biofilms. Pharmaceutics, 8(2).
181- [182] Bjarnsholt, T. (2011). Introduction to biofilms. Biofilm Infections, 1–9.
182- [183] Scriboni, A. B., et al. (2019). Fusogenic liposomes increase the antimicrobial activity of vancomycin against Staphylococcus aureus biofilm. Frontiers in Pharmacology, 10.
183- [184] De Lima, P. H. C., Butera, A. P., Cabeça, L. F., & Ribeiro-Viana, R. M. (2021). Liposome surface modification by phospholipid chemical reactions. Chemistry and Physics of Lipids, 237.
184- [185] Cruz, M. E. M., Corvo, M. L., Martins, M. B., Simões, S., & Gaspar, M. M. (2022). Liposomes as tools to improve therapeutic enzyme performance. Pharmaceutics, 14(3).
185- [186] Sanati, M., & Yavari, S. A. (2024). Liposome-integrated hydrogel hybrids: Promising platforms for cancer therapy and tissue regeneration. Journal of Controlled Release, 368, 703–727.
186- [187] Sun, X., et al. (2019). Bone-targeting drug delivery system of biomineral-binding liposomes loaded with icariin enhances the treatment for osteoporosis. Journal of Nanobiotechnology, 17(1), 1–16.
187- [188] Mishra, V., Chanda, P., Tambuwala, M. M., & Suttee, A. (2019). Personalized medicine: An overview. International Journal of Pharmaceutical Quality Assurance, 10(2), 290–294.
188- [189] Morrison, M., & Kelly, S. (2021). Personalised medicine. In Routledge International Handbook of Critical Issues in Health and Illness (pp. 95–107).
189- [190] Alghamdi, M. A., Fallica, A. N., Virzì, N., Kesharwani, P., Pittalà, V., & Greish, K. (2022). The promise of nanotechnology in personalized medicine. Journal of Personalized Medicine, 12(5).
190- [191] Nikolova, M. P., Kumar, E. M., & Chavali, M. S. (2022). Updates on responsive drug delivery based on liposome vehicles for cancer treatment. Pharmaceutics, 14(10), 1–51.
191- Egorov, E., Pieters, C., Korach-Rechtman, H., Shklover, J., & Schroeder, A. (2021). Robotics, microfluidics, nanotechnology and AI in the synthesis and evaluation of liposomes and polymeric drug delivery systems. Drug Delivery and Translational Research, 11(2), 345–352.
192- Cheng, F., Kovács, I. A., & Barabási, A. L. (2019). Network-based prediction of drug combinations. Nature Communications, 10(1).
193- Schubert, R. (2003). Liposome preparation by detergent removal. Methods in Enzymology, 367, 46–70.
194- Marianecci, C., Petralito, S., Rinaldi, F., Hanieh, P. N., & Carafa, M. (2016). Some recent advances on liposomal and niosomal vesicular carriers. Journal of Drug Delivery Science and Technology, 32, 256–269.
195- Alkilani, A. Z., et al. (2022). Formulation and evaluation of azithromycin-loaded niosomal gel: Optimization, in vitro studies, rheological characterization, and cytotoxicity study. ACS Omega, 7(44), 39782–39793.
196- Sato, Y. T., et al. (2016). Engineering hybrid exosomes by membrane fusion with liposomes. Scientific Reports, 6.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Ruqaya Mohammed Ahmed, Tabarek H. Mahmood, Zain Saleh Al-Tarawneh, Qasim Khalid Alazzawi, Ali Mahmoud Al-Samydai
This work is licensed under a Creative Commons Attribution 4.0 International License.
How to Cite
